NF-κB-mediated neuroinflammation in Parkinson's disease and potential therapeutic effect of polyphenols

SS Singh, SN Rai, H Birla, W Zahra, AS Rathore… - Neurotoxicity …, 2020 - Springer
Different animal and human studies from last two decades in the case of Parkinson's
disease (PD) have concentrated on oxidative stress due to increased inflammation and …

Oxidative stress and neuroinflammation potentiate each other to promote progression of dopamine neurodegeneration

J He, G Zhu, G Wang, F Zhang - Oxidative medicine and …, 2020 - Wiley Online Library
Parkinson's disease (PD) is a chronic and complex disease of the central nervous system
(CNS). Progressive loss of dopamine (DA) neurons in midbrain substantia nigra is …

Aggregated α‐synuclein activates microglia: a process leading to disease progression in Parkinson's disease

W Zhang, T Wang, Z Pei, DS Miller, X Wu… - The FASEB …, 2005 - Wiley Online Library
ABSTRACT A growing body of evidence indicates that an inflammatory process in the
substantia nigra, characterized by activation of resident microglia, likely either initiates or …

Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice

R Iancu, P Mohapel, P Brundin, G Paul - Behavioural brain research, 2005 - Elsevier
Parkinson's disease (PD) is one of the most common neurodegenerative disorders. Several
toxin-induced animals models simulate the motor deficits occurring in PD. Among them, the …

A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function

M Lundblad, B Picconi, H Lindgren, MA Cenci - Neurobiology of disease, 2004 - Elsevier
l-DOPA-induced dyskinesia is a major complication of l-DOPA pharmacotherapy in
Parkinson's disease, and is thought to depend on abnormal cell signaling in the basal …

Connexin 30 deficiency attenuates A2 astrocyte responses and induces severe neurodegeneration in a 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine hydrochloride …

A Fujita, H Yamaguchi, R Yamasaki, Y Cui… - Journal of …, 2018 - Springer
Background The first pathology observed in Parkinson's disease (PD) is 'dying back'of
striatal dopaminergic (DA) terminals. Connexin (Cx) 30, an astrocytic gap junction protein, is …

[HTML][HTML] A partial lesion model of Parkinson's disease in mice–characterization of a 6-OHDA-induced medial forebrain bundle lesion

J Boix, T Padel, G Paul - Behavioural brain research, 2015 - Elsevier
The most frequently used animal models for Parkinson's disease (PD) utilize unilateral
injection of 6-hydroxydopamine (6-OHDA) in the medial forebrain bundle (MFB), which …

Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease

R Sánchez-Pernaute, A Ferree, O Cooper, M Yu… - Journal of …, 2004 - Springer
Several lines of evidence point to a significant role of neuroinflammation in Parkinson's
disease (PD) and other neurodegenerative disorders. In the present study we examined the …

Trophic factor gene therapy for Parkinson's disease

JH Kordower, A Bjorklund - Movement Disorders, 2013 - Wiley Online Library
Parkinson's disease (PD) is a chronic and progressive neurodegenerative movement
disorder for which there is presently no cure. Pharmacological remedies targeting the …

Time course of dopamine neuron loss and glial response in the 6‐OHDA striatal mouse model of P arkinson's disease

SRW Stott, RA Barker - European Journal of Neuroscience, 2014 - Wiley Online Library
Abstract The 6‐hydroxydopamine (6‐OHDA) neurotoxic lesion of the midbrain dopamine
(DA) system is one of the most widely used techniques for modelling Parkinson's disease in …